Table 1.
Clinical Study Population.
| Clinical characteristics | n (%) |
|---|---|
| No. cases | 204 (100) |
| Age at time of diagnosis | |
| <50 years | 90 (44) |
| ≥50 years | 114 (56) |
| Tumor stage (pT) | |
| T1 | 74 (36) |
| T2, T3, T4 | 128 (114; 14; 0) (63) |
| TX (unknown) | 2 (1) |
| Involved lymph nodes | |
| 1–3 | 110 (54) |
| >3 | 94 (46) |
| ER status | |
| positive | 204 (100) |
| HER2/neu status | |
| negative | 204 (100) |
| Therapy | |
| Anthracycline-based plus endocrine therapy | 96 (47) |
| Anthracycline-based without endocrine therapy* | 108 (53) |
| Disease recurrence | |
| Yes | 94 (46) |
| No | 110 (54) |
| Overall survival (event) | |
| Yes | 46 (23) |
| No | 158 (77) |
Clinical and histopathological characteristics of patients (n = 204). *With the ASCO/CAP (American College of Pathology) recommendation in 2010, a consensus threshold reporting ER as positive was set at 1%32. Consequently, prior to the change of guidelines, patients with low level ER expression (between 1% and 10%) were not necessarily treated with endocrine therapy.